A more than 70% stock slide shows that investors are concerned about three as-yet unexplained deaths in a Phase II study of the US firm’s lead candidate.
MacroGenics has seen its share price plummet after Phase II results of its antibody-drug conjugate (ADC) showed a worsening safety profile in metastatic castration-resistant prostate cancer patients, including three as-yet unexplained deaths.
The company’s NASDAQ-listed stock has doubled over the past 12 months, thanks to red-hot investor interest in the ADC field,...
The companies announced the publication of Phase III data that they said provide rationale for moving forward in a confirmatory trial.
The Swiss neuroscience specialist has extended its cash runway into late 2027, but will still need positive readouts in the coming months, including for its wholly owned Parkinson’s candidate.
Amgen and Zai Lab said the final analysis of the FORTITUDE-101 trial showed a decreased magnitude of OS benefit in first-line gastric cancer.
The Phase II study tested AP-101 safety and tolerability as the primary endpoint but showed “clinically meaningful” efficacy in exploratory endpoints.
Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.
The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.
Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.
